Market closed
Olema Pharmaceuticals/$OLMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Ticker
$OLMA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
96
Website
OLMA Metrics
BasicAdvanced
$302M
-
-$2.20
2.12
-
Price and volume
Market cap
$302M
Beta
2.12
52-week high
$16.62
52-week low
$2.86
Average daily volume
945K
Financial strength
Current ratio
10.395
Quick ratio
10.395
Long term debt to equity
0.063
Total debt to equity
0.063
Management effectiveness
Return on assets (TTM)
-24.43%
Return on equity (TTM)
-39.07%
Valuation
Price to book
0.8
Price to tangible book (TTM)
0.8
Price to free cash flow (TTM)
-2.484
Growth
Earnings per share change (TTM)
3.18%
3-year earnings per share growth (CAGR)
7.01%
What the Analysts think about OLMA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Olema Pharmaceuticals stock.
OLMA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
OLMA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
OLMA News
AllArticlesVideos
Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market
Seeking Alpha·2 weeks ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Olema Pharmaceuticals stock?
Olema Pharmaceuticals (OLMA) has a market cap of $302M as of April 20, 2025.
What is the P/E ratio for Olema Pharmaceuticals stock?
The price to earnings (P/E) ratio for Olema Pharmaceuticals (OLMA) stock is 0 as of April 20, 2025.
Does Olema Pharmaceuticals stock pay dividends?
No, Olema Pharmaceuticals (OLMA) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next Olema Pharmaceuticals dividend payment date?
Olema Pharmaceuticals (OLMA) stock does not pay dividends to its shareholders.
What is the beta indicator for Olema Pharmaceuticals?
Olema Pharmaceuticals (OLMA) has a beta rating of 2.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.